ホーム > 市場調査レポート > 医療機器

画像診断核医学

市場調査レポート

商品コード

1446907

医療用アイソトープ市場：タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2023-2032年

Medical Isotope Market By Type (Stable Isotopes, Radioisotopes), By Application (Diagonestic, Nuclear Therapy), By End User (Hospitals, Diagnostic Centers, Research Institutes): Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2024年01月30日 | 発行: Allied Market Research

| ページ情報: 英文 315 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,570 567,522円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,730 910,898円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,526,112円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=158.97円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の医療用アイソトープ市場は、2023年から2032年までのCAGR 8.8%で、2022年の51億4,250万米ドルから成長し、2032年には113億9,790万米ドルに達すると予測されています。

医療用アイソトープは、心臓病やがんなどの健康状態を診断・治療するために医療専門家によって使用されます。医療用アイソトープの生産は、原子炉と粒子加速器（線形加速器、サイクロトロン）という2つの包括的な技術を使用することで達成されます。

核医学は、甲状腺疾患、肺疾患、骨疾患、神経疾患など、さまざまな病気に対する放射線治療を改善するために利用されています。核医学（放射性同位元素）産業は、研究、診断、治療のための放射性物質の使用、SPECTやPETの使用増加、核医学に関するヘルスケア教育や啓発によって特徴付けられています。がん、心血管疾患、神経問題などの疾病の有病率の増加により、核医学画像診断のような精密診断ツールの需要が増加しています。新しい放射性医薬品や画像診断装置が開発されるにつれて、核医学治療はより効果的で安全なものとなっています。このような開発により核医学の用途が広がり、その利用が増加しています。これらの要因が、今後数年間の医療用アイソトープ市場の成長を後押しすると予想されます。

アイソトープとは、陽子の数は同じで中性子の数が変化する化学元素のことです。医療、産業、科学研究など様々な分野で利用されています。しかし、アイソトープの製造や購入は高価であるため、その幅広い利用は制限されています。アイソトープの製造には、原子炉や粒子加速器のような専門的な設備が必要になることが多いです。これらの設備は建設や運営にコストがかかります。アイソトープの取り扱いや製造には厳格な安全規則が必要であり、そのためインフラや操業のコストが上昇します。これらの要因は、予測期間中の医療用アイソトープ市場の成長を制限すると予想されます。

陽電子放出断層撮影法（PET）や単一光子放出コンピュータ断層撮影法（SPECT）のような診断イメージング技術の継続的な進歩は、正確で非侵襲的な医療イメージングに医療用アイソトープを使用する機会を創出します。これらのイメージング技術が進化し続けるにつれて、適切なアイソトープの需要は増加すると思われます。医療用アイソトープの治療用途、特にがん治療（放射性医薬品治療）には大きな成長機会があります。アルファ線放出核種やベータ線放出核種などの標的核種治療の研究開発は、がん治療に使用されるアイソトープの種類の拡大に貢献しています。さらに、核医学放射性同位元素の需要は、新しいSPECTやPETアプリケーションの開発に伴って増加しています。さらに、2021年12月に開催されたRSNA21において、GEヘルスケアは最も高性能な核医学装置であるSPECT/CTを発表しました。これらの進歩は、医療と核医学技術における放射性同位元素の開発を加速すると予想されます。これらすべての要因が、今後数年間の医療用アイソトープ市場の拡大を促進すると予想されます。

COVID-19の大流行は当初、核医学のようなCOVID以外の診断や治療を一時的に中止したり延期したりすることで、核医学ラジオアイソトープ産業にマイナスの影響を与えました。例えば、2021年6月にScienceDirect Journalに掲載された報告によると、COVID-19の症例数と死亡数が増加する一方で、核医学検査、心臓核医学イメージング、がんPET/CTの件数はパンデミックを通じて減少しました。この研究によると、2020年6月から2021年2月にかけて、COVID-19症例が減少したため、手術が増加しました。しかし、2022年初頭からCOVID-19症例が減少したため、放射線処置の面では市場はパンデミック前の水準に近づきつつあり、核医学ラジオアイソトープの需要増につながっています。

利害関係者にとっての主なメリット

当レポートでは、2022年から2032年までの医療用アイソトープ市場分析の市場セグメント、現在の動向、推定・動向、ダイナミクスを定量的に分析し、医療用アイソトープ市場の有力な機会を特定しています。
市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるように、バイヤーとサプライヤーの潜在力を強調します。
医療用アイソトープ市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
市場プレイヤーのポジショニングはベンチマークを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
本レポートには、地域別および世界の医療用アイソトープ市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。

本レポートで可能なカスタマイズ

製品ライフサイクル
技術動向分析
国、地域、世界レベルでの患者/疫学データ
規制ガイドライン
クライアントの関心に応じた追加企業プロファイル
国別または地域別追加分析-市場規模と予測
クリスクロスセグメント分析-市場規模と予測
企業プロファイルの拡張リスト
過去の市場データ
主要プレーヤーの詳細（所在地、連絡先、サプライヤー／ベンダーネットワークなどを含む、エクセル形式）
顧客/消費者/原料サプライヤーのリスト-バリューチェーン分析
世界/地域/国別レベルでのプレーヤーの市場シェア分析
SWOT分析

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- フランス
- ロシア
- イタリア
- その他
アジア太平洋
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- UAE
- 南アフリカ
- その他

第8章競争情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第9章企業プロファイル

Canadian Nuclear Laboratories（CNL）
Curium
GE Healthcare
Jubilant Radiopharma
Nordion Inc.
IBA Radiopharma Solutions
Mallinckrodt Pharmaceuticals
northstar medical radioisotopes, llc
Eczacibasi-Monrol Nuclear Products
Isotopen Technologien Munchen（ITM）

図表

LIST OF TABLES

TABLE 01. GLOBAL MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. MEDICAL ISOTOPE MARKET FOR STABLE ISOTOPES, BY REGION, 2022-2032 ($MILLION)
TABLE 03. MEDICAL ISOTOPE MARKET FOR RADIOISOTOPES, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 05. MEDICAL ISOTOPE MARKET FOR DIAGONESTIC, BY REGION, 2022-2032 ($MILLION)
TABLE 06. MEDICAL ISOTOPE MARKET FOR NUCLEAR THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 08. MEDICAL ISOTOPE MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. MEDICAL ISOTOPE MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. MEDICAL ISOTOPE MARKET FOR RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
TABLE 11. MEDICAL ISOTOPE MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 12. NORTH AMERICA MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA MEDICAL ISOTOPE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 16. U.S. MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 17. U.S. MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 18. U.S. MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 19. CANADA MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 20. CANADA MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 21. CANADA MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 22. MEXICO MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 23. MEXICO MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 24. MEXICO MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 25. EUROPE MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 26. EUROPE MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 27. EUROPE MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 28. EUROPE MEDICAL ISOTOPE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 29. GERMANY MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 30. GERMANY MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. GERMANY MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 32. UK MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 33. UK MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 34. UK MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 35. FRANCE MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 36. FRANCE MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 37. FRANCE MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 38. RUSSIA MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 39. RUSSIA MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 40. RUSSIA MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 41. ITALY MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 42. ITALY MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 43. ITALY MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 44. REST OF EUROPE MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 45. REST OF EUROPE MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 47. ASIA-PACIFIC MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 48. ASIA-PACIFIC MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC MEDICAL ISOTOPE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 51. CHINA MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 52. CHINA MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 53. CHINA MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 54. JAPAN MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 55. JAPAN MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 56. JAPAN MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 57. INDIA MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 58. INDIA MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. INDIA MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 60. SOUTH KOREA MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 61. SOUTH KOREA MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 62. SOUTH KOREA MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 69. LAMEA MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 70. LAMEA MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 71. LAMEA MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 72. LAMEA MEDICAL ISOTOPE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 73. BRAZIL MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 74. BRAZIL MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 75. BRAZIL MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 76. SAUDI ARABIA MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 77. SAUDI ARABIA MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 79. UAE MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 80. UAE MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 81. UAE MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA MEDICAL ISOTOPE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA MEDICAL ISOTOPE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 88. CANADIAN NUCLEAR LABORATORIES (CNL): KEY EXECUTIVES
TABLE 89. CANADIAN NUCLEAR LABORATORIES (CNL): COMPANY SNAPSHOT
TABLE 90. CANADIAN NUCLEAR LABORATORIES (CNL): PRODUCT SEGMENTS
TABLE 91. CANADIAN NUCLEAR LABORATORIES (CNL): SERVICE SEGMENTS
TABLE 92. CANADIAN NUCLEAR LABORATORIES (CNL): PRODUCT PORTFOLIO
TABLE 93. CANADIAN NUCLEAR LABORATORIES (CNL): KEY STRATERGIES
TABLE 94. CURIUM: KEY EXECUTIVES
TABLE 95. CURIUM: COMPANY SNAPSHOT
TABLE 96. CURIUM: PRODUCT SEGMENTS
TABLE 97. CURIUM: SERVICE SEGMENTS
TABLE 98. CURIUM: PRODUCT PORTFOLIO
TABLE 99. CURIUM: KEY STRATERGIES
TABLE 100. GE HEALTHCARE: KEY EXECUTIVES
TABLE 101. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 102. GE HEALTHCARE: PRODUCT SEGMENTS
TABLE 103. GE HEALTHCARE: SERVICE SEGMENTS
TABLE 104. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 105. GE HEALTHCARE: KEY STRATERGIES
TABLE 106. JUBILANT RADIOPHARMA: KEY EXECUTIVES
TABLE 107. JUBILANT RADIOPHARMA: COMPANY SNAPSHOT
TABLE 108. JUBILANT RADIOPHARMA: PRODUCT SEGMENTS
TABLE 109. JUBILANT RADIOPHARMA: SERVICE SEGMENTS
TABLE 110. JUBILANT RADIOPHARMA: PRODUCT PORTFOLIO
TABLE 111. JUBILANT RADIOPHARMA: KEY STRATERGIES
TABLE 112. NORDION INC.: KEY EXECUTIVES
TABLE 113. NORDION INC.: COMPANY SNAPSHOT
TABLE 114. NORDION INC.: PRODUCT SEGMENTS
TABLE 115. NORDION INC.: SERVICE SEGMENTS
TABLE 116. NORDION INC.: PRODUCT PORTFOLIO
TABLE 117. NORDION INC.: KEY STRATERGIES
TABLE 118. IBA RADIOPHARMA SOLUTIONS : KEY EXECUTIVES
TABLE 119. IBA RADIOPHARMA SOLUTIONS : COMPANY SNAPSHOT
TABLE 120. IBA RADIOPHARMA SOLUTIONS : PRODUCT SEGMENTS
TABLE 121. IBA RADIOPHARMA SOLUTIONS : SERVICE SEGMENTS
TABLE 122. IBA RADIOPHARMA SOLUTIONS : PRODUCT PORTFOLIO
TABLE 123. IBA RADIOPHARMA SOLUTIONS : KEY STRATERGIES
TABLE 124. MALLINCKRODT PHARMACEUTICALS: KEY EXECUTIVES
TABLE 125. MALLINCKRODT PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 126. MALLINCKRODT PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 127. MALLINCKRODT PHARMACEUTICALS: SERVICE SEGMENTS
TABLE 128. MALLINCKRODT PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 129. MALLINCKRODT PHARMACEUTICALS: KEY STRATERGIES
TABLE 130. NORTHSTAR MEDICAL RADIOISOTOPES, LLC: KEY EXECUTIVES
TABLE 131. NORTHSTAR MEDICAL RADIOISOTOPES, LLC: COMPANY SNAPSHOT
TABLE 132. NORTHSTAR MEDICAL RADIOISOTOPES, LLC: PRODUCT SEGMENTS
TABLE 133. NORTHSTAR MEDICAL RADIOISOTOPES, LLC: SERVICE SEGMENTS
TABLE 134. NORTHSTAR MEDICAL RADIOISOTOPES, LLC: PRODUCT PORTFOLIO
TABLE 135. NORTHSTAR MEDICAL RADIOISOTOPES, LLC: KEY STRATERGIES
TABLE 136. ECZACIBASI-MONROL NUCLEAR PRODUCTS: KEY EXECUTIVES
TABLE 137. ECZACIBASI-MONROL NUCLEAR PRODUCTS: COMPANY SNAPSHOT
TABLE 138. ECZACIBASI-MONROL NUCLEAR PRODUCTS: PRODUCT SEGMENTS
TABLE 139. ECZACIBASI-MONROL NUCLEAR PRODUCTS: SERVICE SEGMENTS
TABLE 140. ECZACIBASI-MONROL NUCLEAR PRODUCTS: PRODUCT PORTFOLIO
TABLE 141. ECZACIBASI-MONROL NUCLEAR PRODUCTS: KEY STRATERGIES
TABLE 142. ISOTOPEN TECHNOLOGIEN MUNCHEN (ITM): KEY EXECUTIVES
TABLE 143. ISOTOPEN TECHNOLOGIEN MUNCHEN (ITM): COMPANY SNAPSHOT
TABLE 144. ISOTOPEN TECHNOLOGIEN MUNCHEN (ITM): PRODUCT SEGMENTS
TABLE 145. ISOTOPEN TECHNOLOGIEN MUNCHEN (ITM): SERVICE SEGMENTS
TABLE 146. ISOTOPEN TECHNOLOGIEN MUNCHEN (ITM): PRODUCT PORTFOLIO
TABLE 147. ISOTOPEN TECHNOLOGIEN MUNCHEN (ITM): KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. MEDICAL ISOTOPE MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF MEDICAL ISOTOPE MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN MEDICAL ISOTOPE MARKET
FIGURE 04. TOP INVESTMENT POCKETS IN MEDICAL ISOTOPE MARKET (2023-2032)
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. THREAT OF SUBSTITUTION
FIGURE 09. COMPETITIVE RIVALRY
FIGURE 10. GLOBAL MEDICAL ISOTOPE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. REGULATORY GUIDELINES: MEDICAL ISOTOPE MARKET
FIGURE 12. PATENT ANALYSIS BY COMPANY
FIGURE 13. PATENT ANALYSIS BY COUNTRY
FIGURE 14. MEDICAL ISOTOPE MARKET, BY TYPE, 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MEDICAL ISOTOPE MARKET FOR STABLE ISOTOPES, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MEDICAL ISOTOPE MARKET FOR RADIOISOTOPES, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. MEDICAL ISOTOPE MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MEDICAL ISOTOPE MARKET FOR DIAGONESTIC, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MEDICAL ISOTOPE MARKET FOR NUCLEAR THERAPY, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. MEDICAL ISOTOPE MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF MEDICAL ISOTOPE MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF MEDICAL ISOTOPE MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF MEDICAL ISOTOPE MARKET FOR RESEARCH INSTITUTES, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. MEDICAL ISOTOPE MARKET BY REGION, 2022 AND 2032(%)
FIGURE 25. U.S. MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 26. CANADA MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 27. MEXICO MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 28. GERMANY MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 29. UK MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 30. FRANCE MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 31. RUSSIA MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 32. ITALY MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 33. REST OF EUROPE MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 34. CHINA MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 35. JAPAN MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 36. INDIA MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 37. SOUTH KOREA MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 38. AUSTRALIA MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 39. REST OF ASIA-PACIFIC MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 40. BRAZIL MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 41. SAUDI ARABIA MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 42. UAE MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 43. SOUTH AFRICA MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 44. REST OF LAMEA MEDICAL ISOTOPE MARKET, 2022-2032 ($MILLION)
FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 49. COMPETITIVE DASHBOARD
FIGURE 50. COMPETITIVE HEATMAP: MEDICAL ISOTOPE MARKET
FIGURE 51. TOP PLAYER POSITIONING, 2022

Product Code: A74677

The global medical isotopes market is anticipated to reach $11,397.9 million by 2032, growing from $5,142.5 million in 2022 at a CAGR of 8.8% from 2023 to 2032.

Medical isotopes are used by medical professionals to diagnose and treat health conditions such as heart disease and cancer. The production of medical isotopes is achieved by using two overarching technologies: nuclear reactors and particle accelerators (linear accelerators, cyclotrons).

Nuclear medicine is being utilized to improve radiotherapy for a variety of ailments, including thyroid problems, lung diseases, bone diseases, and neurological disorders. The nuclear medicine (radio isotopes) industry is characterized by the use of radioactive materials for research, diagnosis, and therapy, as well as the rising use of SPECT and PET, as well as healthcare education and awareness about nuclear medicine. The increasing prevalence of diseases such as cancer, cardiovascular disease, and neurological issues has led to an increase in the demand for precise diagnostic tools such as nuclear medicine imaging. Nuclear medicine treatments have become more effective and safer as new radiopharmaceuticals and imaging instruments are being developed. These developments have broadened the applications of nuclear medicine and increased its use. These factors are expected to boost the growth of the medical isotopes market in the upcoming years.

Isotopes are chemical elemental varieties with the same number of protons but a variable number of neutrons. They are used in a variety of fields, including medicine, industry, and scientific study. However, the manufacturing and purchase of isotopes can be expensive, limiting their broad use. Isotope production frequently necessitates the use of specialist equipment such as nuclear reactors or particle accelerators. These facilities can be costly to construct and operate. Handling and manufacturing isotopes necessitate tight safety rules, which raises the cost of infrastructure and operations. These factors are expected to limit the growth of the medical isotopes market during the forecast period.

Ongoing advancements in diagnostic imaging technologies, such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), create opportunities for the use of medical isotopes in accurate and non-invasive medical imaging. As these imaging techniques continue to evolve, the demand for suitable isotopes is likely to increase. The therapeutic applications of medical isotopes, particularly in cancer treatment (radiopharmaceutical therapy), offer substantial growth opportunities. R&D in targeted radionuclide therapies, such as alpha and beta emitters, contribute to expanding the range of isotopes used for cancer treatment. In addition, the demand for nuclear medicine radioisotopes is increasing as new SPECT and PET applications are developed. In addition, at RSNA21 in December 2021, GE Healthcare announced its most sophisticated SPECT/CT, a nuclear medicine system. These advances are expected to accelerate the development of radioisotopes in medicine and nuclear medicine techniques. All these factors are anticipated to drive the medical isotopes market expansion in the upcoming years.

The COVID-19 pandemic initially had a negative influence on the nuclear medicine radioisotopes industry by temporarily canceling or postponing non-COVID diagnosis and treatment, such as nuclear medicine. For example, according to a report published in ScienceDirect Journal in June 2021, the number of nuclear studies, nuclear cardiac imaging, and cancer PET/CT reduced throughout the pandemic while COVID-19 cases and deaths increased. According to the study, operations increased from June 2020 to February 2021 as COVID-19 instances decreased. However, with the drop of COVID-19 cases since early 2022, the market in terms of radiological procedures is approaching pre-pandemic levels, which is leading to an increase in demand for nuclear medicine radioisotopes.

The key players profiled in this report include Canadian Nuclear Laboratories (CNL), Curium, GE Healthcare, Jubilant Radiopharma, Nordion (Canada) Inc, IBA Radiopharma Solutions, Mallinckrodt Pharmaceuticals, NorthStar Medical Radioisotopes, Eczacibasi-Monrol Nuclear Products, and Isotopen Technologies Munchen (ITM). The market players are continuously striving to achieve a dominant position in this competitive market using strategies such as collaborations and acquisitions.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the medical isotope market analysis from 2022 to 2032 to identify the prevailing medical isotope market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the medical isotope market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global medical isotope market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Product Life Cycles
Technology Trend Analysis
Patient/epidemiology data at country, region, global level
Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Criss-cross segment analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
List of customers/consumers/raw material suppliers- value chain analysis
Market share analysis of players at global/region/country level
SWOT Analysis

Key Market Segments

By Application

Diagonestic
Nuclear Therapy

By Type

Stable Isotopes
Radioisotopes

By End User

Hospitals
Diagnostic Centers
Research Institutes

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- UAE
- South Africa
- Rest of LAMEA

Key Market Players:

Canadian Nuclear Laboratories (CNL)
Curium
GE Healthcare
Jubilant Radiopharma
Nordion Inc.
IBA Radiopharma Solutions
Mallinckrodt Pharmaceuticals
northstar medical radioisotopes, llc
Eczacibasi-Monrol Nuclear Products
Isotopen Technologien Munchen (ITM)

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
3.5. Market Share Analysis
3.6. Value Chain Analysis
3.7. Regulatory Guidelines
3.8. Patent Landscape

CHAPTER 4: MEDICAL ISOTOPE MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Stable Isotopes
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Radioisotopes
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: MEDICAL ISOTOPE MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Diagonestic
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Nuclear Therapy
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: MEDICAL ISOTOPE MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Diagnostic Centers
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Research Institutes
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: MEDICAL ISOTOPE MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Application
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Type
  - 7.2.5.1.2. Market size and forecast, by Application
  - 7.2.5.1.3. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Type
  - 7.2.5.2.2. Market size and forecast, by Application
  - 7.2.5.2.3. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Type
  - 7.2.5.3.2. Market size and forecast, by Application
  - 7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Application
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Type
  - 7.3.5.1.2. Market size and forecast, by Application
  - 7.3.5.1.3. Market size and forecast, by End User
  - 7.3.5.2. UK
  - 7.3.5.2.1. Market size and forecast, by Type
  - 7.3.5.2.2. Market size and forecast, by Application
  - 7.3.5.2.3. Market size and forecast, by End User
  - 7.3.5.3. France
  - 7.3.5.3.1. Market size and forecast, by Type
  - 7.3.5.3.2. Market size and forecast, by Application
  - 7.3.5.3.3. Market size and forecast, by End User
  - 7.3.5.4. Russia
  - 7.3.5.4.1. Market size and forecast, by Type
  - 7.3.5.4.2. Market size and forecast, by Application
  - 7.3.5.4.3. Market size and forecast, by End User
  - 7.3.5.5. Italy
  - 7.3.5.5.1. Market size and forecast, by Type
  - 7.3.5.5.2. Market size and forecast, by Application
  - 7.3.5.5.3. Market size and forecast, by End User
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Type
  - 7.3.5.6.2. Market size and forecast, by Application
  - 7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Application
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. China
  - 7.4.5.1.1. Market size and forecast, by Type
  - 7.4.5.1.2. Market size and forecast, by Application
  - 7.4.5.1.3. Market size and forecast, by End User
  - 7.4.5.2. Japan
  - 7.4.5.2.1. Market size and forecast, by Type
  - 7.4.5.2.2. Market size and forecast, by Application
  - 7.4.5.2.3. Market size and forecast, by End User
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Type
  - 7.4.5.3.2. Market size and forecast, by Application
  - 7.4.5.3.3. Market size and forecast, by End User
  - 7.4.5.4. South Korea
  - 7.4.5.4.1. Market size and forecast, by Type
  - 7.4.5.4.2. Market size and forecast, by Application
  - 7.4.5.4.3. Market size and forecast, by End User
  - 7.4.5.5. Australia
  - 7.4.5.5.1. Market size and forecast, by Type
  - 7.4.5.5.2. Market size and forecast, by Application
  - 7.4.5.5.3. Market size and forecast, by End User
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Type
  - 7.4.5.6.2. Market size and forecast, by Application
  - 7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Application
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Type
  - 7.5.5.1.2. Market size and forecast, by Application
  - 7.5.5.1.3. Market size and forecast, by End User
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Type
  - 7.5.5.2.2. Market size and forecast, by Application
  - 7.5.5.2.3. Market size and forecast, by End User
  - 7.5.5.3. UAE
  - 7.5.5.3.1. Market size and forecast, by Type
  - 7.5.5.3.2. Market size and forecast, by Application
  - 7.5.5.3.3. Market size and forecast, by End User
  - 7.5.5.4. South Africa
  - 7.5.5.4.1. Market size and forecast, by Type
  - 7.5.5.4.2. Market size and forecast, by Application
  - 7.5.5.4.3. Market size and forecast, by End User
  - 7.5.5.5. Rest of LAMEA
  - 7.5.5.5.1. Market size and forecast, by Type
  - 7.5.5.5.2. Market size and forecast, by Application
  - 7.5.5.5.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Canadian Nuclear Laboratories (CNL)
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Curium
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. GE Healthcare
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Jubilant Radiopharma
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Nordion Inc.
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. IBA Radiopharma Solutions
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Mallinckrodt Pharmaceuticals
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. northstar medical radioisotopes, llc
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. Eczacibasi-Monrol Nuclear Products
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Isotopen Technologien Munchen (ITM)
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments

ライセンス / 価格

Cloud Access (Single User License)

USD 3,570 567,522円

PDF (Business License)

USD 5,730 910,898円

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,526,112円

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=158.97円

お電話でのお問い合わせ

044-952-0102

( 土日・祝日を除く )

アイソトープ

医療用アイソトープ市場：タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2023-2032年

Medical Isotope Market By Type (Stable Isotopes, Radioisotopes), By Application (Diagonestic, Nuclear Therapy), By End User (Hospitals, Diagnostic Centers, Research Institutes): Global Opportunity Analysis and Industry Forecast, 2023-2032

利害関係者にとっての主なメリット

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章医療用アイソトープ市場：タイプ別

第5章医療用アイソトープ市場：用途別

第6章医療用アイソトープ市場：エンドユーザー別

第7章医療用アイソトープ市場：地域別

第8章競争情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Application

By Type

By End User

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: MEDICAL ISOTOPE MARKET, BY TYPE

CHAPTER 5: MEDICAL ISOTOPE MARKET, BY APPLICATION

CHAPTER 6: MEDICAL ISOTOPE MARKET, BY END USER

CHAPTER 7: MEDICAL ISOTOPE MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

医療用アイソトープ市場：タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2023-2032年

Medical Isotope Market By Type (Stable Isotopes, Radioisotopes), By Application (Diagonestic, Nuclear Therapy), By End User (Hospitals, Diagnostic Centers, Research Institutes): Global Opportunity Analysis and Industry Forecast, 2023-2032

利害関係者にとっての主なメリット

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 医療用アイソトープ市場：タイプ別

第5章 医療用アイソトープ市場：用途別

第6章 医療用アイソトープ市場：エンドユーザー別

第7章 医療用アイソトープ市場：地域別

第8章 競争情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Application

By Type

By End User

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: MEDICAL ISOTOPE MARKET, BY TYPE

CHAPTER 5: MEDICAL ISOTOPE MARKET, BY APPLICATION

CHAPTER 6: MEDICAL ISOTOPE MARKET, BY END USER

CHAPTER 7: MEDICAL ISOTOPE MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章医療用アイソトープ市場：タイプ別

第5章医療用アイソトープ市場：用途別

第6章医療用アイソトープ市場：エンドユーザー別

第7章医療用アイソトープ市場：地域別

第8章競争情勢

第9章企業プロファイル